

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: RELTON <i>et al.</i> Appl. No.: 10/587,714 (<i>U.S. National Phase of PCT/US05/02535</i>) Int'l Filing Date: January 28, 2005 For: Treatment of Conditions Involving Dopaminergic Neuronal Degeneration Using Nogo Receptor Antagonists	Confirmation No.: 2306 Art Unit: <i>To Be Assigned</i> Examiner: <i>To Be Assigned</i> Atty. Docket: 2159.0450001/EJH/SAC
--	--

Preliminary Amendment and Submission of Substitute Sequence Listing Under 37 C.F.R. § 1.825

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notification of Missing Requirements Under 37 U.S.C. § 371, dated April 3, 2007, in the above identified matter, and in advance of prosecution, Applicants submit the following amendments and remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments to the specification begin on page 2

Amendments to the claims begin on page 3

Remarks begin on page 7